The American Medical Informatics Association Computer Information Systems Working Group has approved a white paper calling for implementation of basic patient demographic interoperability using IETF vCardDAV across all HIT applications including practice management. Surprisingly this mostly doesn’t exist right now and most have to register and re-register patients basic demographic information manually. It goes to the working group steering committee now for further approval.
Akaza Research announces the availability of version 2.5 of OpenClinica, the popular open source clinical trials software. Full press release after the break.
(Cambridge, MA) September 29, 2008: Akaza Research announces the availability of OpenClinica 2.5, the popular open source clinical trials software. This release marks a major milestone for users of OpenClinica by adding a host of features, many of which are designed to better support regulated industry sponsored clinical trials.
Open source in clinical research will be the topic of a panel discussion at the upcoming DIA Annual Meeting June 24th in Boston.
Join us for an interesting discussion on open source clinical trial software the DIA Annual Meeting June 24th in Boston. This presentation will evaluate how open, standards-based software can alleviate the challenges of flexibility, interoperability, and cost in regulated clinical research environments. Presenters will discuss the unique advantages and challenges in developing and using open source software for tasks such as electronic data capture, and provide an overview of other open source technologies currently being used in clinical trials.
OpenClinica version 2.2 is now available for download. Full press release after the Read More break.
(Cambridge, MA) December 18th, 2007 – Akaza Research announces a new production release of the OpenClinica clinical research software designed for electronic data capture and clinical data management. This new release provides a long list of enhancements across numerous areas of the software. Highlights include:
Connectologist Tim Gee considers patient safety and HealthVault:
Many have criticized HealthVault regarding privacy and security concerns, or perceived limitations of HV as a personal health record (PHR). I suspect that HV is challenged more by the market’s perception of Microsoft’s long running security issues than with any actual shortcomings of that type in HV. And since HV is not a PHR, but rather a “platform,” criticisms about any lack of PHR features is not relevant. One topic I’ve not seen addressed is the safety and effectiveness of the data within HV – and I don’t mean “safety” as in the data is secure from unauthorized access or misuse. I mean “safety” as in the utilization of data stored in HV by other applications won’t result in an unsatisfactory patient outcome, you know, like death or injury.
OpenClinica Enterprise is being adopted to power clinical trials in Australia and New Zeland by Emphron Informatics, a data management and biostatistics contract research organization (CRO). Full press release within.
(Cambridge, MA) August 13, 2007 � Akaza Research, LLC announced today that OpenClinica Enterprise is being adopted by Emphron Informatics, a data management and biostatistics contract research organization (CRO) in Queensland, Australia. Emphron will use OpenClinica Enterprise to help it better manage its customers� clinical trials throughout Australia and New Zealand.
While researching a review article on free/libre and open source in healthcare, I came across some examples of attempts to integrate/bundle GNU/Linux with other health-related applications. I think we have previously mentioned the Care2x/Knoppix tie-up here, but there seem to be several others:
Bioknoppix (http://bioknoppix.hpcf.upr.edu/) is one interesting looking collection from Puerto Rico, and CDMEDICPACS another. All are summarised on http://www.knoppix.net/wiki/Medical_Live_CD
I would be interested in hearing from anyone who has used any of them or knows more about them.
There is an interesting article in Genomics and Proteomics on the dominence of ‘Freeware’ (which is a misnomer in this case, it should say Free/Open Source Software) vs. proprietary software in genomics research: ‘…Whether an academic DNA microarray user is able to use the accompanying software relates to the nature of academic research, Welebob says, and what they are using the software to do. “For academia, researchers are sitting on National Institutes of Health and National Science Foundation grants, and the goal is to get published. To get published, they have to work within very novel space, so they need software packages where they can open the source code and [alter the program] themselves when they need to. They may be doing experiments and experimental designs that are very different than what a commercial package would support, because commercial packages in many ways are built to support more mainstream experimental designs and applications, which represent the largest market.”
U.S. BioDefense to Launch Open Source Platform for Rapid Stem Cell Research and Development. Read on for the complete announcement.
City of Industry, CA � January 21, 2005 – U.S. BioDefense, Inc. (OTCBB: UBDF) announced today that it is developing an Open Source Stem Cell Research Platform to leverage the distributed power of open source development. The Open Source Stem Cell Research Platform will allow researchers at Universities, Government Agencies, and Fortune 500 companies to read, distribute, modify and contribute to stem cell and biotechnology research in an efficient and streamlined method. The platform which can be used as an Intranet or online will provide access to bioinformatic tools and serve as a robust utility for the rapid evolution of Stem Cell technology research, development, and commercialization.
No less a publication than The Economist has this to say about Open Source: ‘Can goodwill, aggregated over the internet, produce good medicine?…Pharmaceutical companies have little incentive to develop treatments for diseases that particularly afflict the poor, for example, since the people who need such treatments most may not be able to afford them.